BlueRock Therapeutics
About
BlueRock Therapeutics is a clinical-stage cell therapy company in Cambridge working to replace cells that are damaged or lost to disease. Rather than relying on traditional treatments, it engineers cell therapies aimed at degenerative conditions, with active programs in neurology and ophthalmology. Its motto, Replace. Restore. Reimagine., sums up the goal of creating medicines in a new way for patients with severe diseases.
Its most advanced program is bemdaneprocel, an investigational cell therapy for Parkinson’s disease that has entered a pivotal Phase III trial and received a Pioneering Regenerative Medical Product designation in Japan. In ophthalmology, lemiretprocel, also known as OpCT-001, is being studied for primary photoreceptor diseases and has received orphan drug designations from the FDA and the European Medicines Agency. The company says it approaches science the way an artist approaches a blank canvas.
What to Know
- Bayer acquired full ownership of BlueRock in 2019.
- The company is a member of the Kendall Square Association.
- BlueRock describes its staff as BlueRockers driven to transform degenerative disease treatment.
- Its research relies on strategic collaborations as well as in-house science.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.